Células madre adiposas humanas disminuyen el daño de la fibrosis hepática con baja persistencia de células trasplantadas en ratas / Human adipose stem cells decrease liver fibrosis damage with low persistence of transplanted cells in rats

RESUMEN: En la enfermedad hepática crónica el trasplante ortotópico es la única alternativa terapéutica actual pero es limitada por falta de donantes. Ensayos con células madre adultas en daño hepático agudo evidencian promisorios resultados. El objetivo de este trabajo fue evaluar en ratas con daño hepático crónico la efectividad de la infusión de células madre adiposas humanas (CMAd-h). Ratas con fibrosis hepática inducida por tioacetamida fueron agrupadas en: grupo I control que no recibió tioacetamida ni células madre, grupo II recibió tioacetamida y suero fisiológico i.v., grupo III recibió tioacetamida y células madre adiposas 1 x 106/kg i.v. vía vena de la cola. La regeneración hepática histológica se evaluó por el index METAVIR, mientras las Macrophagocytus stellatus, células estrelladas a- SMA+ y células colágeno I+ por inmunohistoquímica; el daño funcional se evaluó por los niveles sanguíneos de los analitos Aspartato Aminotransferasa (AST), Alanina Aminotransferasa (ALT), Fosfatasa Alcalina (ALP), úrea y nitrógeno ureico (BUN) y hemograma. Los resultados muestran atenuación del daño estructural hepático evidenciado por disminución de los nódulos, del grado de lesión histológica en el score Metavir, y disminución de Macrophagocytus stellatus, células a-SMA+ y células colágeno tipo I+; funcionalmente hay reducción moderada de AST, ALT, urea, BUN y disminución moderada de células blancas pero efecto favorable sobre el volumen corpuscular media y la hemoglobina corpuscular media. Ocho semanas después de la infusión hay escasa población de CMAd-h en el hígado. En conclusión la infusión intravenosa de CMAd-h en ratas disminuye el daño funcional y estructural de la fibrosis hepática con escasa persistencia de CMAd-h en el parénquima hepático. A nuestro conocimiento este es el primer trabajo que evalúa el efecto de las CMAd-h en el modelo daño hepático crónico murino y la persistencia de las células trasplantadas.

SUMMARY: In chronic liver disease, orthotopic transplantation is the only current therapeutic alternative but it is limited due to lack of donors. Trials with adult stem cells in acute liver damage show promising results. The aim of this work was to evaluate the effectiveness of human adipose stem cell (h-ASC) infusion in rats with chronic liver damage. Rats with thioacetamide- induced liver fibrosis were grouped into: group I control that did not receive thioacetamide and h-ASC, group II received thioacetamide and saline i.v., group III received thioacetamide and h-ASC 1 x 106/ kg i.v. via tail vein. Histological liver regeneration was evaluated by METAVIR index, while Macrophagocytus stellatus (Kupffer cells), stellate cells a-SMA+ and collagen I+ cells by immunohistochemistry; functional damage was evaluated by blood levels of the analytes Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Urea and Blood Urea Nitrogen (BUN) and hemogram. The results show attenuation of structural liver damage evidenced by decreased nodules, degree of histologic injury on Metavir score, and decreased Macrophagocytus stellatus, a-SMA+ cells and type I+ collagen cells; functionally there is moderate reduction of AST, ALT, urea, BUN and moderate decrease of white cells but favorable effect on mean corpuscular volume and mean corpuscular hemoglobin. Eight weeks after infusion there is a small population of h-ASC in the liver. In conclusion, intravenous infusion of h-ASC in rats reduces functional and structural damage of hepatic fibrosis with low persistence of h- ASC in the liver parenchyma. To our knowledge this is the first work that evaluates the effect of h-SC in the model of chronic murine liver damage and the persistence of transplanted cells.

Histological and immunohistochemical evaluation of two cell therapy protocols in equine suspensory ligament repair / Avaliação histológica e imunoistoquímica do reparo do ligamento suspensório equino tratado com dois protocolos de terapia celular

This study aimed to histologically evaluate the quality of tissue repair in equine suspensory ligament treated with two cell therapy protocols. All four limbs of six animals were operated simultaneously to remove a fragment in each ligament using a skin biopsy punch. Two days later, intralesional injections were performed using bone marrow mononuclear fraction (BM group), cultivated cells derived from adipose tissue (AT group), saline (positive control group), or no treatment (negative control group), in such way that each horse received all treatments. After sixty days biopsies were performed for histological analysis (H & E, Masson's trichrome and picrosirius red) and immunohistochemistry analysis (collagen type III). Histological findings (H & E and Masson's trichrome), birefringence intensity (through picrosirius) and collagen type III expression (through immunohistochemistry) were analyzed. Samples from treated groups had better birefringence intensity (P=0.007) and fiber alignment scores were superior compared to controls, though not statistically significant (P=0.08). Presence of inflammatory cells and intense staining for collagen type III occurred in all groups demonstrating an active healing process. In conclusion, both protocols resulted in improvement of tissue repair indicating their potential to be used as an adjuvant treatment of equine suspensory ligament disorders.(AU)

Este estudo teve como objetivo a avaliação histológica e imunoistoquímica do reparo do ligamento suspensório equino tratado com dois protocolos de terapia celular. Os quatro membros dos seis animais do experimento foram submetidos a procedimento cirúrgico em que um fragmento de cada ligamento foi retirado, utilizando-se punch de biópsia. Dois dias após o procedimento, aplicações intralesionais foram realizadas, por meio de aspirado de medula óssea (bone marrow-BM), células mesenquimais derivadas de tecido adiposo (adipose tissue-AT), solução salina (positive control group-PC) ou controle (negative control-NC). Após 60 dias, biópsias foram retiradas da região de reparo dos ligamentos e foram submetidas à análise histológica (HE, tricrômio de Masson, picrosírius red) e imunoistoquímica (colágeno tipo III). Diferentes variáveis histológicas (HE e tricrômio de Masson), a intensidade de birrefringência das fibras colágenas (picrosírius red) e a expressão de colágeno tipo III foram avaliadas. Os grupos tratados apresentaram maior birrefringência (P=0,007) e alinhamento de fibras (P=0,08) comparados ao controle, para o qual o resultado não se mostrou estatisticamente significativo. Achados histológicos e imunoistoquímicos demonstraram um processo ativo de reparo tecidual em todos os grupos. Concluiu-se que os dois protocolos de terapia celular apresentaram melhora no reparo tecidual, demonstrando potencial terapêutico adjuvante no tratamento de afecções do ligamento suspensório equino.(AU)

Matriz porosa do BV60S associada a células osteoprogenitoras alógenas no tratamento de defeitos ósseos críticos em rádios de cães / Porous matrix of BG60S associated with allogenic osteoprogenitor cells in the treatment of critical bone defects in the radius of dogs

O objetivo do estudo foi avaliar o efeito da matriz porosa do biovidro 60S (BV60S) associada a células osteoprogenitoras (CO) alógenas no tratamento de defeitos ósseos críticos de cães. Foram utilizados 20 cães, machos, sem raça definida, com dois anos de idade e massa corporal média de 25kg. Com os cães sob anestesia geral, foram criados defeitos ósseos críticos no terço médio dos ossos rádios. Procedeu-se à fixação óssea com uma placa em ponte, e os defeitos foram tratados de acordo com cada grupo experimental. Constituíram-se três grupos experimentais, em que os defeitos ósseos foram preenchidos com: BV60S associado a CO alógenas (grupo BV60S+CO), osso autógeno (grupo C+), ou não preenchidos (grupo C-). A regeneração óssea foi avaliada por meio de exames radiográficos, densitométricos e histomorfométricos ao longo de 90 dias. Os grupos C- e BV60S+CO mostraram preenchimento ósseo parcial do defeito de, no máximo, 56,68% e 35,23%, respectivamente, sem a formação de ponte óssea entre as extremidades, e o controle positivo (C+) mostrou regeneração óssea completa. Conclui-se que a matriz porosa do BV60S associada às células osteoprogenitoras não é eficiente no tratamento de defeitos ósseos críticos em rádios de cães.(AU)

The objective of this study was to evaluate the effect of the porous matrix of bioglass 60S (BV60S) associated with allogenic osteoprogenitor cells (CO) in the treatment of critical bone defects of dogs. 20 male mongrel dogs at two years old and mean weight of 25kg were used. Dogs were anesthetized and critical bone defects were created in the middle third of the radios bones. With dogs under general anesthesia, critical bone defects were created in the middle third of bone radios. Bone fixation was done with a bridge plate and defects treated according to each experimental group. Three experimental groups were formed according to the treatment. The defects filled with BV60S associated with allogenic CO (Group-BV60S+CO), autogenous bone (Group-C+) or unfilled (Group-C-). Bone regeneration was evaluated by radiography, bone densitometry and histomorphometry over 90 days. The BV60S+CO and C- groups showed partial bone filling of the defect of at most 56.68% and 35.23%, respectively. No bone bridge formation was observed between the extremities in the BV60S+CO and C- groups. Positive control showed complete bone regeneration at 90 days. It was concluded that the porous matrix of BV60S associated with osteoprogenitor cells was not effective in the treatment of critical bone defects in the radius of dogs.(AU)

Mesenchymal Stromal Cells Modulate PAF-stimulated Equine Alveolar Macrophages

Abstract Platelet-activating factor (PAF) is a potent proinflammatory mediator that is produced in increased amounts in the lungs of asthmatic humans and horses. The present pilot study, shows that mesenchymal stromal cells can modulate alveolar macrophage function in asthma, interfering in the activity of PAF, being another potential pathway for mesenchymal stromal cells benefits in asthma.

Células mononucleares autólogas en la reparación de defectos óseos provocados por la periodontitis crónica / Autologous mononuclear cells in the repair of bone defects caused by chronic periodontitis

Introducción: la periodontitis crónica es un proceso inflamatorio de origen bacteriano que afecta a los tejidos del periodonto y provoca la destrucción de los tejidos de soporte del diente. La terapia celular con células mononucleares autólogas constituye una nueva opción terapéutica para lograr la regeneración ósea. Objetivo: evaluar la efectividad del tratamiento con células mononucleares autólogas implantadas en defectos óseos provocados por la periodontitis crónica. Método: estudio cuasiexperimental que se realizó en la Clínica Provincial Docente Antonio Briones Montoto de Pinar del Río, en el periodo comprendido entre enero de 2012 hasta agosto de 2015. A los nueve pacientes del grupo de estudio, se le realizó la perfusión de células mononucleares siete días después de ser intervenidos quirúrgicamente (colgajo periodontal). La movilización a sangre periférica de células mononucleares autólogas se realizó con factor estimulante del crecimiento granulocítico Leukocim (FEC-G). Variables del estudio: dientes afectados, presencia de sangrado al sondeo, bolsas periodontales, movilidad dentaria, pérdida de inserción y evidencia radiográfica. Resultados: posterior a la terapia celular se constató que las encías presentaron características de normalidad a los 7 días de implantados, a los 12 meses se observó hueso de neoformación y aumento de la densidad ósea. Conclusiones: la terapia mostró ser un método factible, simple y seguro en la reparación de defectos óseos provocados por la enfermedad, evidenciando mejoría de los parámetros clínicos y radiográficos(AU)

Introduction: Periodontitis is an inflammatory process of bacterial origin that affects the tissues of the periodontium and causes the destruction of the tissues supporting the tooth. Cell therapy could be an effective therapeutic option to achieve bone regeneration. Objective: To evaluate the effectiveness of treatment with implanted autologous mononuclear cells in bone defects caused by periodontal disease. Methods: A quasiexperimental study was carried out in the Provincial Teaching Clinic Antonio Briones Montoto, Pinar del Río, in the period from January 2012 to August 2015. The nine patients in the study group underwent perfusion of mononuclear cells seven days after surgery (periodontal flap). The mobilization to peripheral blood of autologous mononuclear cells was made with granulocytic leukocyte growth stimulating factor (FEC-G). Study variables: affected teeth, presence of bleeding on probing, periodontal pockets, tooth mobility, loss of insertion and radiographic evidence. Results: After the cell therapy, it was found that the gums showed normality characteristics after 7 days of implantation, after 12 months neoformation bone and increase in bone density was observed. Conclusions: The therapy showed to be a feasible, simple and safe method in the repair of bone defects caused by the disease, evidencing improvement of the clinical and radiographic parameters(AU)

Vascular endothelial growth factor association with angiopoietin 1 promotes improvement in ventricular function after ischemic cardiomyopathy induced in mini pigs

Abstract Purpose: To investigate the safety and clinical, hemodynamic and tissue improvement ability in mini pigs undergoing cell and gene therapy for the treatment of acute myocardial infarction. Methods: Thirty-two mini pigs Br1 lineage, 12 months old, undergoing induction of acute myocardial infarction by occlusion of the diagonal branch of the paraconal coronary. They were divided into 4 groups: one control group and 3 treatment groups (cell therapy and gene cell therapy). Echocardiography reviews were performed on three occasions and histopathological analysis was performed after 4 weeks. Analysis of variance (ANOVA), Tukey and Wilcoxon tests, were performed. Results: Association of vascular endothelial growth factor (VEGF) with angiopoietin1 (Ang1) presented satisfactory results in the improvement of ventricular function following ischemic cardiomyopathy in mini pigs when compared to the results of the other treated groups. Conclusion: The therapy with VEGF and the combination of VEGF with Ang1, promoted recovered function of the myocardium, characterized by reduced akinetic area and induction of neovascularization.

Novas abordagens terapêuticas na Doença de Chagas: terapia celular, anticorpos, aférese / New therapheutic approaches in Chagas Disease stem cell antibodies apheresis

A doença de Chagas é considerada, atualmente, pela Organização Mundial da Saúde uma das doenças tropicais negligenciadas, com estimativa de mais de 8 milhões de pessoas infectadas em todo o mundo. Recentemente tem havido crescente interesse na doença de Chagas, importante etiologia de miocardiopatia na América Latina, devido, em grande parte, ao aumento da incidência dessa doença em países desenvolvidos. A despeito do amplo emprego de drogas antiparasitárias na forma aguda da doença de Chagas, o tratamento etiológico da miocardiopatia chagásica crônica permanece incerto, sendo o benefício para o prognóstico dos pacientes ainda indeterminado. No presente artigo realizamos revisão sistemática a respeito do emprego de terapia celular, anticorpos, vacinas e plasmaferese em pacientes com doença de Chagas. Os dados levantados indicam que, a despeito de a terapia baseada em células-tronco mostrar potencial benéfico em modelos experimentais, em seres humanos, a evidência até o momento disponível não nos autoriza a utilizar tal modalidade na rotina assistencial. Vacinas baseadas em antígenos genéticos têm potencial a ser explorado, mas sem aplicabilidade momentânea em seres humanos. Novos estudos são necessários para elucidar o uso real dessas modalidades alternativas no contexto da miocardiopatia chagásica.

ABSTRACT The World Health Organization, with an estimate of over 8 million people infected worldwide, currently considers the Chagas disease as one of the neglected tropical diseases. Recently there has been increasing interest in Chagas disease, an important etiology of cardiomyopathy in Latin America, due in large part to the increased incidence in developed countries. Despite the widespread use of antiparasitic drugs in the acute infected form of Chagas disease, etiological treatment of chronic Chagas cardiomyopathy remains uncertain, and the benefit for the prognosis of patients still undetermined. In the present article, we present a systematic review on the use of cell therapy, antibodies, vaccines and plasmapheresis in patients with Chagas disease. The data collected indicate that, despite the stem cell-based therapy showing beneficial potential in experimental models, in humans, the evidence so far available does not allows us to use this modality as a routine treatment. Vaccines based on genetic antigens have potential to be explored, but without immediate applicability in humans. Further studies are needed to elucidate the actual use of these alternative methods in the context of Chagas cardiomyopathy.

Bacterial cellulose and bacterial cellulose/polycaprolactone composite as tissue substitutes in rabbits' cornea / Celulose bacteriana e composto de celulose bacteriana/policaprolactone para substituto tissular na córnea de coelho

In order to test the performance of bacterial cellulose/polycaprolactone composite (BC/PCL) and pure bacterial cellulose (BC) as tissue substitutes in rabbits' cornea, a superficial ulcer containing 5mm in diameter and 0.2mm deep was made in the right cornea of 36 rabbits, then a interlayer pocket was created from the basis of this ulcer. Twelve rabbits received BC/PCL membrane and 12 were treated with BC membranes, both membranes with 8mm in diameter. The remaining rabbits received no membrane constituting the control group. The animals were clinically followed up for 45 days. Three animals of each group were euthanized at three, seven, 21, and 45 days after implantation for histological examination of the cornea along with the implant. Clinical observation revealed signs of moderate inflammatory process, decreasing from day 20th in the implanted groups. Histology showed absence of epithelium on the membranes, fibroplasia close to the implants, lymph inflammatory infiltrate with giant cells, collagen disorganization, with a predominance of immature collagen fibers in both groups with implants. Although inflammatory response is acceptable, the membranes used does not satisfactorily played the role of tissue substitute for the cornea during the study period.(AU)

Com objetivo de testar o desempenho do compósito celulose bacteriana/policaprolactona (CB/PCL) e da celulose bacteriana pura (CB) como substitutos teciduais em córnea de coelhos, foi realizada uma úlcera superficial de 5 mm de diâmetro e 0,2 mm de profundidade na córnea direita de 36 coelhos, criando-se um bolso interlamelar a partir da base dessa úlcera. Doze animais receberam a membrana do compósito CB/PCL e 12 foram tratados com membranas de CB, ambas com 8 mm de diâmetro, os coelhos restantes não receberam nenhuma membrana, constituindo o grupo controle. Os animais foram acompanhados clinicamente até 45 dias. Três animais de cada grupo sofreram eutanásia aos três, sete, 21 e 45 dias após o implante das membranas para análise histológica da córnea juntamente com o implante. À observação clínica, houve sinais de processo inflamatório moderado, diminuindo a partir do 20º dia nos grupos implantados. A histologia demonstrou ausência de epitélio sobre as membranas, fibroplasia próxima aos implantes, infiltrado inflamatório linfo-histiocitário com células gigantes, desorganização do colágeno, com predominância de fibras imaturas de colágeno em ambos os grupos com implantes. Embora a resposta inflamatória seja aceitável, as membranas utilizadas não desempenharam satisfatoriamente o papel de substituto tecidual para a córnea, no período estudado.(AU)

Dos herramientas de la biología sintética / Two synthetic biology's tools

La Biología sintética llegó para quedarse y expandir los límites de la ciencia. Numerosas técnicas moleculares que están siendo empleadas hoy en muchos laboratorios superaron la ficción para convertirse en una realidad. En este artículo se presentan dos técnicas innovadoras de la Biología sintética, como son la técnica de CRISPR, en especial la aplicación de CRISPR-on en la activación de genes específicos humanos, y el uso de ARN mensajeros sintéticos para la purificación y aislamiento celular. Con una mirada enfocada en la medicina traslacional, las herramientas de la Biología sintética ofrecen un gran potencial terapéutico. (AU)

Synthetic biology came to settle in and break the boundaries of the science. Many molecular techniques overcome the fiction to become reality. This article discusses two innovative techniques, as CRISPR, in particular the application of CRISPR-on which is able to activated particular human genes, and the synthetic RNAs messengers for isolation and purification specific cells. From a gaze focused on translational medicine, both tools offer great therapeutic potential. (AU)

Membrana amniótica: fonte alternativa de células-tronco mesenquimais em diversas espécies animais / Amniotic membrane: alternative source of mesenchymal stromal cells in several animals species

O crescente interesse do uso de células-tronco (CTs) na medicina regenerativa, estão baseadas na sua capacidade de autorrenovação, reparação tecidual e imunomodulação. A terapia utilizando células-tronco é uma ciência em formação considerada uma alternativa terapêutica promissora no tratamento de diversas patologias degenerativas, hereditárias e inflamatórias. A busca por fontes alternativas de CTs que possuam características como fácil obtenção e isolamento, tem levado ao estudo dos mais variados tecidos, onde se inclui os anexos embrionários como a membrana amniótica. Porém, para sua efetiva aplicação terapêutica são necessários estudos de suas características "in vitro", além de testes pré-clínicos e clínicos. Com isso, o objetivo deste trabalho é realizar uma revisão bibliográfica sobre a caracterização e aplicação clínica das células-tronco da membrana amniótica em diversas espécies de animais domésticos.(AU)

The increasing interest for the use of stem cells in regenerative medicine, is based on their self-renewal capacity, tissue repair and immunomodulation. The therapy with stem cells is a science in formation considered a promising therapeutic alternative for the treatment of various degenerative, hereditary and inflammatory disorders. The search for alternative sources of stem cells of easy obtention and isolation has led to the study of various tissues, includng embryonic attachments such as the amniotic membrane. However for effective therapeutic application are needed studies of the characteristics in vitro and preclinical and clinical trials. Thus, the aim of this study was a literature review regarding the characterization and clinical application of stem cells from the amniotic membrane in several domestic animal species.(AU)

Comparação de dois métodos de colheita de medula óssea de equinos e de dois meios de diluição para o isolamento de células mononucleares / Comparison of two methods of equine bone marrow aspiration and two solutions for mononuclear cell isolation

O objetivo do presente estudo foi avaliar a concentração e viabilidade da fração de células mononucleares (FCM) a partir de diferentes técnicas de colheita e processamento de medula óssea (MO) em equinos. Foram avaliados cinco equinos adultos, hígidos e sem raça definida. Obtiveram-se frações de medula óssea (MO) do osso esterno, de acordo com dois protocolos: na colheita A, utilizou-se 10mL de solução de heparina dentro da seringa e em seguida, aspirou-se a MO; na colheita B, 10mL de solução de heparina foi injetada na MO e a aspiração foi realizada após 20 segundos. Todos os animais foram submetidos aos dois protocolos de colheitas, realizadas em sequência, sem intervalo entre os dois procedimentos. Após isolamento da fração de células mononucleares (FCM), das amostras de MO obtidas nas colheitas A e B, cada amostra foi dividida em dois tubos, um contendo solução de DMEM e outro contendo PBS. Assim, alternando-se o tipo de colheita e a solução diluidora, obteve-se quatro tubos de amostras por animal. Os tubos foram centrifugados e os sedimentos foram homogeneizados nos respectivos meios obtendo-se o volume final de 100μL. Realizou-se determinação da concentração e viabilidade celular, obtendo-se as concentrações médias de FCM. Para ambos os meios de diluição, a colheita B apresentou valor numérico maior em comparação à colheita A, porém não foi significativo (p>0,05). Atribui-se tal tendência à menor ocorrência de coagulação da MO no momento da colheita B, sugerindo-se melhor aproveitamento da FCM. Não houve diferença (p>0,05) entre os meios DMEM ou PBS, indicando que os mesmos não alteraram a viabilidade celular. Os protocolos utilizados para colheita de MO e separação da FCM se mostraram eficientes, para o uso em terapia celular em equinos.

The aim of this study was to evaluate mononuclear cells fraction (MCF) concentration and viability from different techniques of bone marrow (BM) aspiration and processing in horses. Five adult horses, healthy and of unknown breed were evaluated. BM was obtained from sternum bone, according two protocols: in aspiration A, 10mL of heparin solution was used inside the syringe and BM was aspirated; in aspiration B, 10mL of heparin solution was injected into the BM, and aspiration was done after 20 seconds. All the animals were submitted by both protocols realized in sequence, without a gap between the procedures. After MCF isolation, of BM samples obtained from A and B aspiration, each sample was divided into two tubes; one contained DMEM solution and the other with PBS solution. Therefore, interchanging the aspiration protocol and the dilution solution, four sample tubes were obtained for each horse. The tubes were centrifuged and the pellet was homogenized with the respectively solution to obtain the final volume of 100μL. Cellular concentration and viability were determined to obtain the FCM medium concentration. For both solutions, the aspiration B had higher numeric values comparing with aspiration A; however, it was not significant (p>0.05). This tendency is attribute for the less BM coagulation observed in the aspiration B, suggesting greater improvement of MCF. No difference (p>0.05) was found between DMEM and PBS solution, indicating that both do not alter the cell viability. The protocols used for BM aspiration and MCF isolation were efficient for application in equine cellular therapy.

Which is the best route of administration for cell therapy in experimental model of small-for size syndrome in rats?

PURPOSE: To evaluate which is the best route of administration for cell therapy in experimental rat model of small-for size syndrome. METHODS: A total of 40 rats underwent partial hepatectomy (70%) that induces the small-for-size syndrome and were divided into four groups of route administration: intravenous, intraperitoneal, enteral and tracheal. The small-for-size syndrome model was designed with extended partial hepatectomy (70%). The animals were divided into four groups of routes administration: intravenous (n=10) - intravenously through the dorsal vein of the penis; intraperitoneal (n=10) - intraperitoneally in the abdominal cavity; enteral (n=10) - oroenteral with the placement of a number 4 urethral probe and maintained at third duodenal portion; tracheal (n=10) - after tracheal intubation. We track the animals and monitor them for 21 days; during this follow-up we evaluated the result of cell therapy application tracking animals using ultrasound, radiography and PET-scan. Statistical analysis was performed using GraphPad Prism Software(r). Differences were considered significant with the p<0.05. Data are presented as the median and variation for continuous variables. Comparisons between groups were made using analysis of the imaging test by the researchers. RESULTS: All four groups underwent partial hepatectomy of 70% liver tissue targeting the same weight of resected liver. Initially the PET-scan tests showed similarity in administered cells by different routes. However, in few days the route of intravenous administration showed to be the most appropriated to lead cells to the liver followed by enteral. The tracheal and peritoneal routes were not as much successful for this goal. CONCLUSION: The intravenous route is the best one to cell therapy in experimental rat model of small-for size-syndrome. .

Cell-based therapy for kidney disease

The prevalence of renal disease continues to increase worldwide. When normal kidney is injured, the damaged renal tissue undergoes pathological and physiological events that lead to acute and chronic kidney diseases, which frequently progress to end stage renal failure. Current treatment of these renal pathologies includes dialysis, which is incapable of restoring full renal function. To address this issue, cell-based therapy has become a potential therapeutic option to treat renal pathologies. Recent development in cell therapy has demonstrated promising therapeutic outcomes, in terms of restoration of renal structure and function impaired by renal disease. This review focuses on the cell therapy approaches for the treatment of kidney diseases, including various cell sources used, as well recent advances made in preclinical and clinical studies.

Aplicação de células-tronco mesenquimais no tratamento de lesões raquimedulares naturalmente adquiridas em cães e em gatos domésticos / Application of mesenchymal stem cells in the treatment of naturally acquired spinal cord injuries in dogs and domestic cats

Mecanismos de lesão e suas consequencias decorrentes de injúria da medula espinhal (IME) envolvem morte neuronal tanto por necrose quanto por apoptose. Sabendo-se que a regeneração do sistema nervoso central é limitada após danos tissulares, é crucial o desenvolvimento de novas abordagens que otimizem o retorno funcional após IME. As opções de tratamento tardio em cães e em gatos não estão disponíveis e os aspectos de segurança e terapeutico do transplante autólogo de células-tronco mesenquimais derivadas de medula óssea (BMMC) não foram ainda descritas anteriormente. O objetivo desta pesquisa é isolar e caracterizar as BMMC em cães e em gatos; selecionar cães e gatos com IME crônica; elaborar uma abordagem terapeutica à IME utilizando BMMC...

Lesion mechanisms and its evolution following spinal cord injury (SCI) involves neuronal death by both necrosis and apoptosis. Since regeneration of the central nervous system is limited after injuries, it is crucial to develop novel approaches that optimize functional recovery aft er SCI. Stem cell-based therapy has been investigated in a number of degenerative and traumatic diseases, including SCI. Late spinal cord injury treatment options in dogs and cats are not available. Neither the safety aspects and therapeutic effects of autologous bone marrow mesenchymal stem cell (BMMC)...

In vitro cultivation of canine multipotent mesenchymal stromal cells on collagen membranes treated with hyaluronic acid for cell therapy and tissue regeneration

Support structures for dermal regeneration are composed of biodegradable and bioresorbable polymers, animal skin or tendons, or are bacteria products. The use of such materials is controversial due to their low efficiency. An important area within tissue engineering is the application of multipotent mesenchymal stromal cells (MSCs) to reparative surgery. The combined use of biodegradable membranes with stem cell therapy may lead to promising results for patients undergoing unsuccessful conventional treatments. Thus, the aim of this study was to test the efficacy of using membranes composed of anionic collagen with or without the addition of hyaluronic acid (HA) as a substrate for adhesion and in vitro differentiation of bone marrow-derived canine MSCs. The benefit of basic fibroblast growth factor (bFGF) on the differentiation of cells in culture was also tested. MSCs were collected from dog bone marrow, isolated and grown on collagen scaffolds with or without HA. Cell viability, proliferation rate, and cellular toxicity were analyzed after 7 days. The cultured cells showed uniform growth and morphological characteristics of undifferentiated MSCs, which demonstrated that MSCs successfully adapted to the culture conditions established by collagen scaffolds with or without HA. This demonstrates that such scaffolds are promising for applications to tissue regeneration. bFGF significantly increased the proliferative rate of MSCs by 63% when compared to groups without the addition of the growth factor. However, the addition of bFGF becomes limiting, since it has an inhibitory effect at high concentrations in culture medium.

Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study.

Background & objectives: Bone marrow mononuclear cell therapy has emerged as one of the option for the treatment of Stroke. Several preclinical studies have shown that the treatment with mononuclear cell (MNCs) can reduce the infarct size and improve the functional outcome. We evaluated the feasibility, safety and clinical outcome of administering bone marrow mononuclear cell (MNCs) intravenously to patients with subacute ischaemic stroke. Methods: In a non-randomized phase-I clinical study, 11 consecutive, eligible and consenting patients, aged 30-70 yr with ischaemic stroke involving anterior circulation within 7 to 30 days of onset of stroke were included. Bone marrow was aspirated from iliac crest and the harvested mononuclear cells were infused into antecubital vein. Outcomes measured for safety included immediate reactions after cell infusion and evidence of tumour formation at one year in whole body PET scan. Patients were followed at week 1, 4-6, 24 and 52 to determine clinical progress using National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), modified Rankin Scale (mRS), MRI, EEG and PET. Feasibility outcomes included target-dose feasibility. Favourable clinical outcome was defined as mRS score of 2 or less or BI score of 75 to 100 at six months after stem cell therapy. Results: Between September 2006 and April 2007, 11 patients were infused with bone-marrow mononuclear cells (mean 80 million with CD-34+ mean 0.92 million). Protocol was target-dose feasible in 9 patients (82%). FDG-PET scan at 24 and 52 wk in nine patients did not reveal evidence of tumour formation. Seven patients had favourable clinical outcome. Interpretation & conclusions: Intravenous bone marrow mononuclear cell therapy appears feasible and safe in patients with subacute ischaemic stroke. Further, a randomized controlled trial to examine its efficacy is being conducted.

Isquemia de membros inferiores: perspectiva atual da terapia celular e terapia gênica / Lower limb ischemia: current outlook for cell therapy and gene therapy

O estágio dos sintomas do paciente com doença isquêmica de membros inferiores determina o tipo detratamento. Apesar das terapias já conhecidas um grupo desses pacientes não é candidato ao tratamento cirúrgicoou continua com dor mesmo após o tratamento, o que afeta a sua qualidade de vida. O entendimento dosmecanismos moleculares envolvidos no desenvolvimento vascular possibilita respeitar e compreender os benefíciose limites das terapias moleculares para o tratamento das doenças isquêmicas de membros inferiores. Neste artigodescreve-se a perspectiva atual da terapia celular e da terapia gênica no tratamento da isquemia crítica demembros inferiores.

Stem cell therapy: A novel & futuristic treatment modality for disaster injuries.

Stem cell therapy hold the potential to meet the demand for transplant cells/tissues needed for treating damages resulting from both natural and man-made disasters. Pluripotency makes embryonic stem cells and induced pluripotent stem cells ideal for use, but their teratogenic character is a major hindrance. Therapeutic benefits of bone marrow transplantation are well known but characterizing the potentialities of haematopoietic and mesenchymal cells is essential. Haematopoietic stem cells (HSCs) have been used for treating both haematopoietic and non-haematopoietic disorders. Ease of isolation, in vitro expansion, and hypoimmunogenecity have brought mesenchymal stem cells (MSCs) into limelight. Though differentiation of MSCs into tissue-specific cells has been reported, differentiation-independent mechanisms seem to play a more significant role in tissue repair which need to be addressed further. The safety and feasibility of MSCs have been demonstrated in clinical trials, and their use in combination with HSC for radiation injury treatment seems to have extended benefit. Therefore, using stem cells for treatment of disaster injuries along with the conventional medical practice would likely accelerate the repair process and improve the quality of life of the victim.